Industry & Policy News

[Fierce Biotech] BrainStorm Cell Therapeutics has been determined to get a twice-rejected amyotrophic lateral sclerosis treatment through the FDA process.

[Direct Biologics, LLC] Direct Biologics, LLC announced that the FDA has authorized the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo™ in the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS) from any underlying etiology.

[UC Riverside] A new UC Riverside training program will help undergraduates transition into regenerative medicine careers, infusing the Inland Empire wraith expertise in cutting-edge trauma and disease treatments.

[Disc Medicine, Inc.] Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a Phase II clinical study of patients with DBA.

[Abcuro Inc.] ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells. Inclusion body myositis is an autoimmune disease in which highly cytotoxic T cells chronically attack muscle tissue causing patients to progressively lose muscle function, including loss of grip, dexterity, and mobility.

[University of Leicester] The British Heart Foundation has awarded nearly £900,000 to University of Leicester professor, Matthew Brown, to continue his pioneering heart valve research.